



Page numbers in *italics* indicate tables/exhibits.

## A

Acceptance and commitment therapy (ACT), 31

Accreditation Council for Pharmacy Education, 171

Acetaminophen, 11, 139

Acupuncture, 8

Acute opioid overdose, treatment of, 73–74, 75–78

Acute pain. *See* Pain

Acute withdrawal, treatment of, 79–80

Addiction, 27–29

Affirmation, statements of, 50

Age and opioid use disorders (OUDs), 3

Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), 44

Alcoholics Anonymous, 57, 153

Alcohol Use Disorders Identification Test (AUDIT), 44

Alcohol Use Disorders Identification Test (AUDIT-C), 45–47, 48

Alternative therapies for pain, 8–9

Ambulatory care settings. *See* Community care/ambulatory care settings

American Action Forum (AAF), 10

American Association of Colleges of Pharmacy (AACP), 163–164

SAPE report, 168–169

American College of Obstetricians and Gynecologists (ACOG), 126, 127

American Medical Association, 5

American Pain Society (APS), 5

American Pharmacists Association (APhA), 145

American Psychiatric Association, 28

American Society of Addiction Medicine (ASAM), 27–29, 126, 156

Amphetamines, detection time of, 59

Anterior cingulate cortex, 25

Assessment. *See* Screening

## B

Barbiturates, detection time of, 59

Benzodiazepines, 3

    detection time of, 59

Betty Ford Consensus Panel, 32

Biomedical and psychosocial needs, addressing of, 64–65

Bio-psycho-social-spiritual OUD recovery programs, 98–99

“Black box” warnings, 3

Brain, the. *See* Neurobiology

Breastfeeding and neonatal abstinence syndrome (NAS), 139, 140

Brief intervention, 40, 44, 50–51

Buprenorphine

    for acute pain in patient with current active opioid use disorder, 96

    combination with naloxone, 80–81

    detection time of, 59

    long-acting formulations of, 81

    in medication-assisted therapy, 60, 62, 80–82

    metabolism of, 60

    for neonatal abstinence syndrome (NAS), 138

in opioid treatment program (OTP),  
98–99  
for pregnant women, 129, 130–131  
Burglaries and robberies, 111–112

## C

CAGE-AID, 47, 49  
Cannabinoids, detection time of, 59  
Celebrate Recovery, 57  
Centers for Disease Control and Prevention (CDC), 2, 71, 72  
on methadone, 7  
Centers for Medicare & Medicaid Services (CMS), 8  
Chiropractic manipulation, 9  
Chronic/maintenance treatment options, 80–83  
Chronic pain. *See* Pain  
Clinical drug testing, 57–59  
*Clinical Drug Testing in Primary Care*, 59  
Clinical indications for opioids in acute and chronic pain, 95  
Clinical Opiate Withdrawal Scale (COWS), 79  
Clonidine, 79, 139  
Cocaine, 35  
detection time of, 59  
Codeine, metabolism of, 60  
Code of Federal Regulations, 53, 106  
Cognitive behavioral therapy (CBT), 31  
*Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders, A*, 136  
Collateral damage of the opioid epidemic, 10–11  
Community care/ambulatory care settings  
caring for the patient with chronic pain and an SUD in, 61–62  
clinical drug testing in, 57–59  
controlled-substance agreements and monitoring, 54–55  
counseling and support groups in, 57  
education of patients and caregivers in, 59–61  
medication checks in, 56  
Community pharmacy practices in diversion, 104–108  
*Confidentiality of Alcohol and Drug Abuse Patient Records, CFR*, 53

Controlled-substance agreements and monitoring, 54–55  
Controlled Substances Act of 1970, 4  
Core content development, 171–172  
Corticotropin releasing factor (CRF), 27  
Council of Economic Advisors, 4  
Counseling and support groups, 57  
Crack cocaine, 35  
Criminal justice system and opioid epidemic, 10  
Criteria and terminology used to define opioid use disorders, 38, 39  
Cross study, 153–154  
Cue-induced relapse, 26  
Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease, 168–169  
Curriculum. *See* Education  
Cyclobenzaprine, 79

## D

Deaths. *See* Overdose, opioid  
Department of Health and Human Services (DHHS), 1, 82  
Detection and deterrence. *See also* Prescription drug monitoring programs (PDMPs)  
community pharmacy practices and, 104–112  
diversion strategies and, 104–116  
of doctor and pharmacy shopping, 104–105  
hospital practices and, 115–116  
introduction to, 103  
outpatient practices and, 113–114  
and prevention of fraud and deception, 105–106  
and prevention of prescriber-driven diversion, 108–111  
and prevention of prescription forgeries, 106–108  
rationales for medication diversion and, 103–104  
of shortages, theft, and loss of prescription medications, 111–112  
Detection times of common drugs of misuse, 58, 59  
Detoxification, inpatient, 63–64  
Diagnosis. *See* Screening

Diagnostic and Statistical Manual of Mental Disorders (DSM), 28–29, 38, 39, 147, 163

Dialectical behavioral therapy (DBT), 31

Discrepancy, developing, 51

Diversion, medication. *See also* Prescription drug monitoring programs (PDMPs)

- community pharmacy practices in, 104–108
- hospital practices in, 115–116
- introduction to, 103
- outpatient practices in, 113–114
- rationales for, 103–104
- strategies in, 104–116

Doctor-shopping, 9, 104–105, 113

Dopamine, 25–26

- glutamate and, 26

Drug Abuse Screening Test (DAST), 44, 47, 49

Drug Enforcement Agency (DEA) numbers, 107

Drugs of choice, 35–36

Drug testing, 114

Dynorphin, 27

---

## E

Economic burden of opioid use disorders (OUDs), 4, 10

Education

- core content development for, 171–172
- curricular considerations, 171
- curricular recommendations summary, 166–167
- enhancing postgraduate SUD, 174
- extent of curricular adoption, 168
- history of SUD curricular development for, 163–171
- introduction to, 163
- of patients and caregivers by pharmacists, 59–61, 66–67
- for pharmacy technicians, 172–174
- recent curricular projects, 168–171
- recommendations, 171–174
- recommended SUD curriculum goals for, 165
- summary of, 174–175

Elderly population, increases in, 8

Emergency department visits, 63, 74

Empathy, expressions of, 50

Epidemiology of opioid use disorders (OUDs), 2–4

Ethical priorities and pain management, 93–94

Evidence-based treatment of chronic pain, 4–5

---

## F

Family separations due to opioid misuse, 1, 11

Federation of State Medical Boards, 5

Fentanyl, 3, 4–5

- derivatives, import of synthetic, 9
- overdose deaths due to, 71, 72–73

Fifth vital sign, pain as, 5

Finnegan Abstinence Scoring system, 136

Food and Drug Administration (FDA), 3, 6–7, 72–73

Forgeries, prescription, 106–108

Fraud, detection of, 105–106

Functional magnetic resonance imaging (fMRI), 25

---

## G

Gender and opioid use disorders (OUDs), 3

Geographic factors in opioid use disorders (OUDs), 2–3

Glutamate, 26

Guidelines for treatment of chronic pain, 4–5

---

## H

Health insurance, 8–9

Health Insurance Portability and Accountability Act (HIPAA), 53

Health professionals, SUDs in

- chronic pain issues and, 150
- compared to SUDs in pharmacy professionals, 150–151
- Cross study on, 153–154
- inadequate education/training regarding, 149
- introduction to, 145
- job dissatisfaction and, 148
- job-related stress and, 148
- learning to detect and take care of, 155–156
- peer/pharmacy culture reinforcement of self-medication practices and, 150
- pharmaceutical knowledge contributing to feelings of invulnerability and, 149

pharmacy technicians and, 151  
 pharmacy workplace as high-risk work  
 environment for, 147–150  
 relapse of, 152–154  
 risk of, 146–150  
 student pharmacists and, 152  
 summary of, 159–160  
 treatment and aftercare issues for,  
 156–159  
 unprecedented access to medications  
 and, 149–150

Health-system settings  
 addressing biomedical and psychosocial  
 needs in, 64–65  
 addressing mental health concerns in, 66  
 emergency department, 63  
 inpatient detoxification in, 63–64  
 intensive outpatient and partial  
 hospitalization programs, 64  
 patient education in, 66–67  
 treatment of acute opioid overdose in,  
 73–74, 75–78

Hedonic system, 27

Hepatitis, 1, 11

Heroin, 3, 35

metabolism of, 60

Hospital Consumer Assessment of  
 Healthcare Providers and Systems  
 (HCAHPS) survey, 8

Hospital practices and diversion, 115–116

Human immunodeficiency virus (HIV), 1, 11

Hydrocodone, 3

metabolism of, 60

Hydromorphone, 4

metabolism of, 60

Hydroxyzine, 79

## I

Identification theft, 113

Illegal distribution of controlled substances,  
 9

Incidence of opioid use disorders (OUDs), 2

Inpatient detoxification, 63–64

Institute for Healthcare Improvement (IHI),  
 136

Insular cortex, 25

Intensive outpatient and partial  
 hospitalization programs, 64

Interventional pain procedures, 9

Intrapartum care for OUDs in pregnancy,  
 132

## J

Job dissatisfaction, 148

Joint Commission for the Accreditation of  
 Healthcare Organizations, 5

Journal of the American Pharmacists  
 Association, 36

## L

Liking and wanting, 26

Lipsitz Scoring Tool, 136

Listening, reflective, 51

Long-acting opioids, 5–6

unintended consequences of, 7

Loperamide, 79

## M

Marketing of opioids, 6–7

Massage, 9

Maternal Opioid Treatment: Human  
 Experimental Research (MOTHER) study,  
 125

Meconium, 136

Medically supervised withdrawal for  
 pregnant women, 131

Medication-assisted therapy (MAT), 31,  
 54, 60–61. See also Pharmacotherapy  
 treatment

for pharmacy professionals, 154

in postpartum care, 132

for pregnant women, 128–133

Medication checks, 56, 114

Medications for treatment of opioid use  
 disorder. See Pharmacotherapy treatment

Mental health concerns, addressing of, 66

Metabolism of opiates/opioids, 60

Methadone, 3

detection time of, 59

in medication-assisted therapy, 60, 62,  
 82–83

metabolism of, 60

for neonatal abstinence syndrome (NAS),  
 138

for pregnant women, 128–130

unintended consequences of, 7

Milner, Peter, 24

Mindfulness-based therapies, 31  
 Monitoring. *See also* Prescription drug monitoring programs (PDMPs)  
 in community care/ambulatory care settings, 54–55  
 neonatal abstinence syndrome (NAS), 136  
 Morphine, 3, 4  
 for acute pain in patient with current active opioid use disorder, 96  
 metabolism of, 60  
 for neonatal abstinence syndrome (NAS), 138  
 MOTHERS trial, 136

## N

Naloxone, 74, 75–78  
 combination with buprenorphine, 80–81  
 Naltrexone, 83, 154  
 for pregnant women, 131  
 Narcan nasal spray, 75–78  
 Narcotics Anonymous, 57, 153  
 National Alliance of Mental Illness, 53  
 National Institute on Alcohol Abuse and Alcoholism (NIAAA) Clinician's Guide, 45  
 National Institute on Drug Abuse (NIDA), 49–50, 60  
 National Surveys on Drug Use and Health, 8  
 Natural recovery, 30  
 Neonatal abstinence syndrome (NAS), 1, 10, 125. *See also* Pregnancy, opioid use disorder in  
 assessment and monitoring of, 136  
 breastfeeding and, 139, 140  
 clinical presentation of, 134–135  
 diagnosis of, 135–136  
 interdisciplinary approach to treatment of, 136–137  
 introduction to, 133–134  
 nonpharmacologic management of, 139, 140  
 pharmacological management of, 137–138, 138–139  
 post-delivery follow-up for, 140  
 role of the pharmacist in treating and preventing, 140–141  
 scope of problem, 134  
 Neonatal Narcotic Withdrawal Index, 136  
 Neonatal Withdrawal Inventory, 136  
 Neurobiology, 23–24, 32–33  
 cue-induced relapse and, 26

of the high-risk brain, 94–95, 98  
 substance-induced relapse and, 25  
 SUD pathophysiology and, 24–25  
 SUD symptomatology and, 27–29  
 Neuroimaging, 25  
*New England Journal of Medicine*, 6  
 NIDA-Modified Alcohol, Smoking, and Substance Involvement Screening Test (NM ASSIST), 50  
 N-methyl-D-aspartate (NMDA) receptor, 7  
 Nucleus accumbens (NAc), 24

## O

Observable signs of opioid use disorder, 37–38  
 Olds, James, 24  
 Ondansetron, 139  
 Open-ended questions, 51  
 Open School's Plan-Do-Study-Act (PDSA), 136–137  
 Opiates. *See* Opioids  
 Opioids  
 associated with overdoses and deaths, 3  
 clinical indications for, 95  
 detection times of, 58, 59  
 development of new, more potent, and long-acting, 5–6  
 as drugs of choice, 35–36  
 financial incentives to prescribe, dispense, and divert, 9  
 import of counterfeit, 9  
 management of acute withdrawal from, 79–80  
 metabolism of, 60  
 pediatric poisonings with, 1, 11  
 pharmaceutical marketing of, 6–7  
 Opioid treatment program (OTP), 96, 98–99  
 Opioid use disorders (OUDs)  
 acute pain in patient currently recovering from, 97  
 acute pain in patient with current active, 95–96  
 advances arising from epidemic of, 12  
 age, gender, race, and, 3  
 caring for patients with current or past, who also have severe chronic pain, 98–99  
 chronic pain in patient currently recovering from, 99–100

chronic pain in patient with current active, 97–98

collateral damage of, 10–11

criteria and terminology used to define, 38, 39

defining, 35

detection and deterrence of (See Detection and deterrence)

economic burden of, 4, 10

epidemiology of, 2–4

geographic factors in, 2–3

inadequate treatment resources for, 8

incidence of, 2

increased prevalence of, 8, 71

introduction to, 1–2

neonates and (See Neonatal abstinence syndrome (NAS))

observable signs of, 37–38

origins of, 4–10

pharmacist's role in addressing, 12–13

pharmacists' brief patient interventions for, 40

potential consequences associated with, 40–41

in pregnancy (See Pregnancy, opioid use disorder in)

specific opioids associated with, 3

symptoms of, 37–38, 154–156

Orbitofrontal cortex (OFC), 25

Origins of the opioid epidemic, 4–10

Outpatient practices and diversion, 113–114

Overdose, opioid

  deaths, contributing factors in, 72–73

  treatment of acute, 73–74, 75–78

Oxycodone, 3

  metabolism of, 60

OxyContin, 6–7

## P

### Pain

alternative therapies for, 8–9

caring for patients with current or past OUD who also have severe chronic, 98–99

caring for the patient with an SUD and, 61–62

chronic, in health professionals, 150

clinical indications for opioids in acute and chronic, 95

in currently sober former opioid misuser, acute, 97

in currently sober former opioid misuser, chronic, 99–100

evidence-based and guidelines for treatment of chronic, 4–5

as the fifth vital sign, 5

high-risk brain and, 94–95, 98

increasing elderly population resulting in increased prevalence of chronic, 8

introduction to, 93

keeping basic ethical priorities straight in addressing, 93–94

in patient with current active OUD, acute, 95–96

in patient with current active OUD, chronic, 97–98

summary of treatment of SUD and, 100–101

undertreated, 11

Partial hospitalization programs, 64

Pathophysiology of substance use disorders, 24–25

Patient education, 59–61, 66–67

Pediatric poisonings, 1, 11

Pharmacist recovery network (PRN) programs, 156

Pharmacists

  addressing stigma, 53–54

  being familiar with counseling and support groups, 57

  brief intervention by, 44, 50–51

  brief patient interventions by, 40

  caring for the patient with chronic pain and an SUD, 61–62

  chronic pain issues in, 150

  clinical drug testing and, 57–59

  community care/ambulatory care settings and, 54–62

  controlled-substance agreements and monitoring and, 54–55

  education of patients and caregivers by, 59–61, 66–67

  enhancing postgraduate SUD training for, 174

  feelings of invulnerability to SUDs in, 149

  health-system setting care and, 63–67

  inadequate education/training regarding SUDs in, 149

  job dissatisfaction in, 148

  job-related stress in, 148

medication checks by, 56

National Institute on Drug Abuse (NIDA)  
resources for, 49–50

peer/pharmacy culture reinforcement of  
self-medication practices in, 150

public opinions of, 145

quick approach to screening by, 47–49

referrals for treatment by, 44, 51–53

role in addressing the opioid epidemic,  
12–13

role in interprofessional care team for  
pregnant women with OUDs, 126

role in preventing and treating NAS,  
140–141

screening for substance use disorders by,  
43–45

standard approach to screening by,  
45–47

student, 152

substance use disorders in (See Health  
professionals, SUDs in)

unprecedented access to medications by,  
149–150

Pharmacotherapy treatment. *See also*  
Treatment and recovery management

acute withdrawal management, 79–80

buprenorphine-containing medications  
in, 80–82

chronic/maintenance, 80–83

methadone, 82–83

naloxone, 74, 75–78

naltrexone, 83

for neonatal abstinence syndrome (NAS),  
137–138, 138–139

non-FDA approved/experimental  
treatment options for, 84

for pharmacy professionals, 154

for pregnant women, 128–133

provider limitations, 82, 83

summary of, 84–85

Pharmacy shopping, 104–105

Pharmacy technicians  
education about SUDs for, 172–174

SUDs in, 151

Phencyclidine, detection time of, 59

Phenobarbital, 139

Pill counts and medication checks, 56, 114

Pill mills, 9, 108–111

Point-of-care drug testing, 57–58

Postpartum care for OUDs in pregnancy,  
132–133, 140

Pregnancy, opioid use disorder in. *See also*  
Neonatal abstinence syndrome (NAS)

barriers to treatment engagement for, 128

intrapartum care for, 132

introduction to, 125–126

medically supervised withdrawal for, 131

medication-assisted therapy for, 128–131

postpartum care for, 132–133, 140

role of pharmacist in interprofessional  
care team for, 126

screening and assessment of, 126–127

treatment for, 128–133

Prescriber-driven diversions, 108–111

Prescription drug monitoring programs  
(PDMPs), 9, 71–72, 172

access to, 117

limitations of, 119–120

overview of, 116–117

reporting of aberrant or suspected  
criminal actions in, 120

as tool for detection and deterrence,  
118–119

Prescription forgeries, 106–108

Productivity losses due to opioid misuse, 10,  
40–41

Promethazine, 79

Psychosocial needs, 64–65

Purdue Pharma, 6–7

---

## Q

Quick approach to screening, 47–49

---

## R

Race and opioid use disorders (OUDs), 3

Referral for treatment, 44, 51–53

Reflective listening, 51

Relapse of SUDs in pharmacy professionals,  
152–154

Risk Evaluation and Mitigation Strategy  
(REMS), 81

Risky use, 45, 46–47

---

## S

Screening  
National Institute on Drug Abuse (NIDA)  
resources on, 49–50

neonatal abstinence syndrome (NAS),  
135–136

for OUDs in pregnant women, 126–127  
 quick approach to, 47–49  
 screening, brief intervention, and referral to treatment (SBIRT) process, 43–45, 53  
 standard approach to, 45–47  
 Secular Organizations for Sobriety, 57  
 Separation of families due to opioid misuse, 1, 11  
 Simethicone, 139  
 Standard approach to screening, 45–47  
 Stigma, 53–54  
 Stress, job-related, 148  
 Stress-induced relapse, 27  
 Structural massage, 9  
 Substance abuse, 28  
 Substance Abuse and Mental Health Services (SAMHSA), 59, 60, 65, 83, 126, 136  
*Substance Abuse Treatment for Persons with Co-Occurring Disorders*, 66  
 Substance dependence, 28  
 Substance-induced relapse, 25–26  
 Substance use disorders (SUDs), 1–2, 9  
 and the brain, 23–24  
 care in the community and ambulatory care settings for, 54–62  
 care in the health-system setting for, 63–67  
 caring for patients with chronic pain and, 61–62  
 cue-induced relapse, 26  
 definition of, 45  
 detection and deterrence of (See Detection and deterrence)  
 DSM-IV on, 28  
 education on (See Education)  
 factors that potentially place individuals at higher risk for, 36  
 in health professionals (See Health professionals, SUDs in)  
 pain and (See Pain)  
 pathophysiology of, 24–25  
 pharmacist screening for, 43–45  
 standard approach to screening for, 45–47  
 stigma of, 53–54  
 stress-induced relapse, 27  
 substance-induced relapse, 25  
 symptomology, 27–29  
 Substance Use Risk Profile-Pregnancy screening tool, 127  
 Suicidality, 63

Supervised injection facilities (SIF), 84  
 Support groups, 57  
 Symptomology, SUD, 27  
 Symptoms of opioid use disorder, 37–38  
 neonatal abstinence syndrome (NAS), 134–135  
 in pharmacy professionals, 154–156  
 Synthetic fentanyl, 9

---

## T

Theft, 111–112  
 identification, 113  
 Treatment and recovery management, 9, 29.  
 See also Pharmacotherapy treatment acute opioid overdose, 73–74, 75–78  
 bio-psycho-social-spiritual OUD recovery programs for, 98–99  
 commonalities of people in, 30–31  
 community based (See Community care/ ambulatory care settings)  
 in health-system settings (See Health-system settings)  
 natural recovery, 30  
 neonatal abstinence syndrome (NAS), 136–137  
 in pharmacy professionals, 152–159  
 for pregnant women with OUDs, 128–133  
 prescription drug monitoring programs (PDMPs) in, 9, 71–72, 116–120, 172  
 specific strategies in, 31–32  
 Treatment cycling, 31

---

## U

Umbilical cord sampling, 136  
 Undertreated pain, 11  
 Uniform Controlled Substances Act of 1970, 120  
 Universal urine drug testing (UDT), 127

---

## V

Ventral tegmentum area (VTA), 24  
 Veteran's Administration (VA), 5

---

## W

Wanting and liking, 26  
 Withdrawal symptoms of opioid use disorder, 37–38, 98  
 World Health Organization (WHO), 126





